Category: Regulatory DisclosuresBy adminNovember 17, 2022 Author: admin https://ramedapharma-ir.com Post navigationPreviousPrevious post:Rameda Reports its 3Q22 ResultsNextNext post:Disclosure to EGX on Treasury SharesRelated PostsRameda Announces New Chairman and Additions to its Board of DirectorsJune 3, 2026Rameda Initiates First Acquisition of 2025July 7, 2025Record Dividend Distribution DisclosureJuly 7, 2025BOD-Shareholding-Structure-2024April 15, 2024The invitation to shareholders for the AGMMarch 31, 2024RetractionMarch 24, 2024
